News | Ablation Systems | November 14, 2016

Catheter Ablations Reduce Long-Term Stroke Risk in Patients with Prior Stroke History

Intermountain study finds stroke rates similar between atrial fibrillation patients treated with ablation and patients with no history of AFib

catheter ablations, atrial fibrillation, stroke risk, Intermountain Medical Center Heart Institute study, AHA Scientific Sessions, American Heart Association

November 14, 2016 — Atrial fibrillation patients with a prior history of stroke who undergo catheter ablation lower their long-term risk of a recurrent stroke by 50 percent, according to new research from the Intermountain Medical Center Heart Institute.

Atrial fibrillation is an abnormal heart rhythm caused by rogue electrical currents in the heart. The arrhythmia allows blood to pool and clot in the heart. When the clot breaks loose, it travels to the brain and causes a stroke.

When medications are not successful in treating the arrhythmia, catheter ablations are used to create scar tissue in the upper left atrium of the heart that prevents rapid, chaotic electric currents, often from the pulmonary veins, from causing the abnormal rhythm.

“One of the most devastating complications of atrial fibrillation is a stroke and its prevention is the treatment cornerstone of the abnormal heart rhythm,” said Jared Bunch, M.D., lead author of the study and director of electrophysiology at the Intermountain Medical Center Heart Institute in Salt Lake City. “Patients that have a prior history of stroke have a much greater risk of recurrent strokes. Our new research shows the more successful we are in treating the abnormal rhythm through the process required with catheter ablation, the better chance we have of lowering a patient’s long-term risk of stroke.”

Results of the study were presented during the American Heart Association’s Scientific Sessions, Nov. 12-16 in New Orleans.

The Intermountain study compared a group of 140 patients, who had a prior history of stroke and underwent their first catheter ablation, to two other patient groups, both of which also had a prior history of stroke, including 416 atrial fibrillation patients who did not receive a catheter ablation, and 416 stroke patients who did not have atrial fibrillation.

The patients were followed for five years and observed for recurrent outcomes of stroke, heart failure and death.

The five-year risk of patients having another stroke was decreased in the patients who had a catheter ablation to treat atrial fibrillation, compared to the group that had no catheter ablation to treat their abnormal heart rhythm. The stroke rates of atrial fibrillation patients that underwent an ablation procedure were similar to patients with no history of atrial fibrillation.

“One of the most important findings of this study was that stroke rates in patients that underwent an ablation were similar to patients with no history of atrial fibrillation. This suggests that our management approach can alter some of the negative effects and natural history of atrial fibrillation. As physicians, we spend a lot of our time and energy trying to prevent stroke. This study helps us understand better how our management approaches can alter stroke risk,” said Bunch. “Our research shows that more aggressive treatment of atrial fibrillation by using catheter ablations will reduce the chances a person will have a life-threatening stroke.”

Other members of the Intermountain Medical Center Heart Institute team include Heidi T. May, Ph.D.; Tami L. Bair, RN; Victoria Jacobs, Ph.D.; Brian G. Crandall, M.D.; Michael Cutler, M.D.; Jeffrey S. Osborn, M.D.; Charles Mallender, M.D.; John D. Day, M.D.; and Peter Weiss, M.D.

For more information: www.scientificsessions.org

Related Content

Noninvasive Radioablation Offers Long-term Benefits to High-risk Heart Arrhythmia Patients
News | Ablation Systems | September 17, 2019
September 17, 2019 — Treating high-risk heart patients with a single, high dose of radiation therapy can dramatically
Biosense Webster Announces Initial Results From First-in-Human QDOT-FAST Study
News | Ablation Systems | May 16, 2019
Johnson & Johnson Medical Devices Companies announced that Biosense Webster, Inc.’s QDot Micro catheter...
CardioFocus Announces Results From HeartLight X3 Ablation System Pivotal Study
News | Ablation Systems | May 16, 2019
CardioFocus Inc. announced the presentation of results from its pivotal confirmatory study evaluating the HeartLight X3...
New Global Consensus Statement Addresses Catheter Ablation of Ventricular Arrhythmias
News | Ablation Systems | May 14, 2019
The Heart Rhythm Society (HRS) in partnership with three other professional societies issued an international consensus...
Netherlands Hospital to Install State-of-the-Art MRI Ablation Center
News | Ablation Systems | May 13, 2019
Imricor announced the signing of a commercial agreement with the Haga Hospital in The Hague, Netherlands to outfit a...
A CyberHeart cardiac ablation radiotherapy treatment plan showing where the radiation beam will ablate for a noninvasive pulmonary vein isolation procedure. Varian acquires, buys, purchases Cyberheart.

A CyberHeart cardiac ablation radiotherapy treatment plan showing where the radiation beams will ablate for a noninvasive pulmonary vein isolation procedure to treat an arrhythmia.

Feature | Ablation Systems | May 10, 2019 | Dave Fornell, Editor
May 10, 2019 — Radiation oncology vendor Varian announced it acquired the start-up company CyberHeart, which has deve
Ablation Reduces Risk of Dementia in Patients With AFib and Carotid Artery Disease
News | Ablation Systems | May 08, 2019
Even though many medical practitioners may opt not to perform procedures on higher-risk patients, new research finds it...
CardioFocus Announces European CE Mark Approval Of HeartLight X3 System
News | Ablation Systems | April 16, 2019
CardioFocus Inc. announced the European CE Mark approval of the HeartLight X3 Endoscopic Ablation System.
First Patient Treated With QDot Micro Ablation Catheter
News | Ablation Systems | February 04, 2019
Biosense Webster has enrolled and treated the first patient in its U.S. Investigational Device Exemption (IDE) study...
Overlay Init